180 related articles for article (PubMed ID: 25008867)
1. Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.
Sugishita M; Imai T; Kikumori T; Mitsuma A; Shimokata T; Shibata T; Morita S; Inada-Inoue M; Sawaki M; Hasegawa Y; Ando Y
Breast Cancer; 2016 Mar; 23(2):195-201. PubMed ID: 25008867
[TBL] [Abstract][Full Text] [Related]
2. A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.
Sawyer MB; Pituskin E; Damaraju S; Bies RR; Vos LJ; Prado CM; Kuzma M; Scarfe AG; Clemons M; Tonkin K; Au HJ; Koski S; Joy AA; Smylie M; King K; Carandang D; Damaraju VL; Hanson J; Cass CE; Mackey JR
Clin Breast Cancer; 2016 Apr; 16(2):139-44.e1-3. PubMed ID: 26452313
[TBL] [Abstract][Full Text] [Related]
3. Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients.
Islam MS; Islam MS; Parvin S; Ahmed MU; Bin Sayeed MS; Uddin MM; Hussain SM; Hasnat A
Tumour Biol; 2015 Jul; 36(7):5451-7. PubMed ID: 25677905
[TBL] [Abstract][Full Text] [Related]
4. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
Okishiro M; Kim SJ; Tsunashima R; Nakayama T; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Apr; 132(3):947-53. PubMed ID: 21706156
[TBL] [Abstract][Full Text] [Related]
5. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
Vulsteke C; Lambrechts D; Dieudonné A; Hatse S; Brouwers B; van Brussel T; Neven P; Belmans A; Schöffski P; Paridaens R; Wildiers H
Ann Oncol; 2013 Jun; 24(6):1513-25. PubMed ID: 23396606
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of the Risk Factors of Febrile Neutropenia Among 72 Women Receiving FEC in Early Breast Cancer Chemotherapy].
Ishii N; Fujimori T; Kasagawa T; Udagawa I
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1555-1557. PubMed ID: 28133055
[TBL] [Abstract][Full Text] [Related]
8. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
[TBL] [Abstract][Full Text] [Related]
9. GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy.
Deng X; Yang X; Cheng Y; Liu X; Li X; Zhao R; Qin C; Lu Q; Yin C
Sci Rep; 2015 Sep; 5():14000. PubMed ID: 26354850
[TBL] [Abstract][Full Text] [Related]
10. Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.
Charehbili A; de Groot S; van der Straaten T; Swen JJ; Pijl H; Gelderblom H; van de Velde CJ; Nortier JW; Guchelaar HJ; Kroep JR
Pharmacogenomics; 2015; 16(11):1267-76. PubMed ID: 26289095
[TBL] [Abstract][Full Text] [Related]
11. Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.
Ludovini V; Antognelli C; Rulli A; Foglietta J; Pistola L; Eliana R; Floriani I; Nocentini G; Tofanetti FR; Piattoni S; Minenza E; Talesa VN; Sidoni A; Tonato M; Crinò L; Gori S
BMC Cancer; 2017 Jul; 17(1):502. PubMed ID: 28747156
[TBL] [Abstract][Full Text] [Related]
12. Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.
Zhou X; Wang X; Song Q; Yang H; Zhu X; Yu J; Song G; Di L; Ren J; Shao H; Lyerly HK
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):914-22. PubMed ID: 26396136
[TBL] [Abstract][Full Text] [Related]
13. Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.
Vulsteke C; Pfeil AM; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Peeters M; van Dam P; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
Breast Cancer Res Treat; 2014 Oct; 147(3):557-70. PubMed ID: 25168315
[TBL] [Abstract][Full Text] [Related]
14. Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors.
Pfeil AM; Vulsteke C; Paridaens R; Dieudonné AS; Pettengell R; Hatse S; Neven P; Lambrechts D; Szucs TD; Schwenkglenks M; Wildiers H
BMC Cancer; 2014 Mar; 14():201. PubMed ID: 24641830
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Masuda N; Higaki K; Takano T; Matsunami N; Morimoto T; Ohtani S; Mizutani M; Miyamoto T; Kuroi K; Ohno S; Morita S; Toi M
Cancer Chemother Pharmacol; 2014 Aug; 74(2):229-38. PubMed ID: 24871032
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer.
Zhang BL; Sun T; Zhang BN; Zheng S; Lü N; Xu BH; Wang X; Chen GJ; Yu DK; Lin DX
Chin Med J (Engl); 2011 Jan; 124(2):199-204. PubMed ID: 21362365
[TBL] [Abstract][Full Text] [Related]
17. High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial.
Callens C; Debled M; Delord M; Turbiez-Stalain I; Veyret C; Bièche I; Brain E
Breast Cancer Res Treat; 2015 Sep; 153(2):383-9. PubMed ID: 26318989
[TBL] [Abstract][Full Text] [Related]
18. Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer.
Przybylowska-Sygut K; Stanczyk M; Kusinska R; Kordek R; Majsterek I
Clin Breast Cancer; 2013 Feb; 13(1):61-8. PubMed ID: 23103366
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer.
Eckhoff L; Feddersen S; Knoop AS; Ewertz M; Bergmann TK
Acta Oncol; 2015 Apr; 54(4):530-7. PubMed ID: 25383449
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
